A Study to Evaluate the Effect of Miebo™ on Preoperative Biometry/Keratometry and Postoperative Refractive Accuracy

Inclusion Criteria:

1. At least 18 years of age at the time of consent

2. Able to provide written voluntary informed consent

3. The same eye must satisfy the below inclusion criteria (a-e):

4. At least 1 eye with a visually significant cataract that has been scheduled forcataract surgery (eligible eye can be a subject's second eye to undergocataract surgery as long as all eligibility criteria are met in that eye)

5. Candidate for routine, uncomplicated cataract surgery (phacoemulsification withposterior chamber intraocular lens [IOL] implantation, not combined with anyother surgery)

6. In the Investigator's opinion, subject has potential postoperative pinholeSnellen visual acuity of at least 20/200 in both eyes

7. Tear film break-up time ≤10 sec at Visit 1

8. Total CFS score ≥2 and ≤11 (ie, sum of inferior, superior, central, nasal, andtemporal), using the National Eye Institute scale at Visit 1

9. Ocular Surface Disease Index (OSDI) ≥23 at Visit 1

10. Able and willing to follow instructions, including participation in all trialassessments and visits.

Exclusion Criteria:

1. Have any clinically significant ocular surface slit-lamp findings in the study eyeand/or, in the opinion of the Investigator, have any findings that could interferewith trial parameters, including:

2. History of eye trauma

3. History of Stevens-Johnson syndrome

4. Active blepharitis or lid margin inflammation

5. DED secondary to scarring, irradiation, alkali burns, cicatricial pemphigoid,or destruction of conjunctival goblet cells (as with vitamin A deficiency)

6. Abnormal lid anatomy causing incomplete eyelid closure

7. Abnormal cornea shape (keratoconus)

8. Corneal epithelial defect or significant confluent staining or filaments

9. History of herpetic keratitis

10. Ocular or periocular rosacea

11. Pterygium in either eye

12. Use of any of the following ocular therapies in the study eye within 30 days priorto Visit 1: Vuity®, Qlosi™, topical ocular steroid treatments, prescription dry eyetherapy including varenicline nasal spray, or topical anti-glaucoma medication

13. Had a LipiFlow® procedure, intense pulse light procedure, or any kind of otherprocedure affecting meibomian glands in the study eye within 3 months prior to Visit 1

14. Had received or removed a permanent punctum plug in the study eye within 1 month (3months for dissolvable punctum plugs) prior to Visit 1

15. Use of any eye drops (prescription or over-the-counter, such as artificial tears orLumify®) and/orTrueTear™ device (intranasal tear neurostimulator) in the study eyewithin 24 hours prior to Visit 1

16. Have active ocular allergies or ocular allergies that are expected to be activeduring the trial period

17. Have worn contact lenses within 1 month prior to Visit 1 or planned wear during thestudy

18. Have undergone intraocular surgery or ocular laser surgery in the study eye within 3months prior to Visit 1; have undergone refractive surgery in the study eye within 2years prior to Visit 1

19. Have active ocular or systemic infection (bacterial, viral, or fungal), includingfever

20. Female subjects who are pregnant, nursing, or planning a pregnancy

21. Female subjects of childbearing potential who are not using an acceptable means ofbirth control; acceptable methods of contraception include hormonal (oral,implantable, injectable, or transdermal) contraception; mechanical (spermicide inconjunction with a barrier such as a diaphragm or condom) contraception;intrauterine device; or surgical sterilization of partner. For non-sexually activefemale subjects, abstinence may be regarded as an adequate method of birth control;however, if the subject becomes sexually active during the trial, she must agree touse adequate birth control as defined above for the remainder of the trial.

22. Have an uncontrolled systemic disease that, in the opinion of the Investigator, willinterfere with the trial

23. Have a known allergy and/or sensitivity to the investigational drug

24. Use of any oral medications known to cause ocular drying (eg, antihistamines,antidepressants, etc.) on a non-stable regimen within 1 month prior to Visit 1 or isexpected to be unstable during the trial

25. Have taken isotretinoin (eg, Accutane, Myorisan, Claravis, Amnesteem) within 6months prior to Visit 1

26. Are currently enrolled in an investigational drug or device study or had used aninvestigational drug or device within 60 days prior to Visit 1.